Dentsply Sirona Unit Rolls Out 24-Hour Surity Male Catheter for 13M U.S. Patients
Dentsply Sirona subsidiary Wellspect HealthCare launched the Surity Male External Catheter in the U.S., following an earlier female version and ahead of its Urinary Management System rollout. The non-invasive device targets over 13 million Americans with severe urinary incontinence, offering up to 24-hour wear, see-through placement and a slim, skin-friendly design.
1. Product Launch Details
Wellspect HealthCare has introduced the Surity Male External Catheter to its U.S. portfolio, featuring a see-through design for easy placement, a slim profile to minimize bulk and skin-friendly materials for up to 24 hours of continuous wear. The device is compatible with standard urine collection systems and is now available for direct home purchase, with institutional availability planned soon.
2. Market Opportunity
Severe urinary incontinence affects more than 13 million Americans, creating a significant addressable market. This launch builds on positive feedback from the Surity Female External Catheter, highlighting unmet needs for comfortable, discreet and user-friendly continence solutions in the male segment.
3. Strategic Implications for Dentsply Sirona
As part of Dentsply Sirona, Wellspect’s expansion into male continence care could drive recurring revenue growth and strengthen its urological device lineup alongside LoFric catheters and Navina irrigation systems. The Surity portfolio extension underscores the company’s focus on comprehensive continence management and long-term market positioning.